Nephrotoxicity of Iodixanol versus Iopamidol in Patients Undergoing Peripheral Angiography with or without Endovascular Therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015835

Enrollment

Unknown

Registered

2018-04-24

Start date

2014-03-01

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral vascular disease

Interventions

iodixanol group:iodixanol

iopamidol group:iopamidol

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients were considered to be eligible if they were over 18 years and met the 2011 ESC guideline recommendations for peripheral intervention therapy.

Exclusion criteria

Exclusion criteria: (1) pregnancy; (2) preexisting dialysis; (3) estimated glomerular filtration rate (eGFR)1 angiography during hospitalization were also excluded in our study.

Design outcomes

Primary

Measure	Time frame
incidence of contrast induced nephropathy (CIN);	—

Countries

China

Contacts

Public ContactJiang Xiongjing

Dept. of Cardiology, Fuwai Hospital, Chinese academy of Medical Sciences and Peking Union Medical College

jiangxiongjing@163.com+86 13601088445

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026